IDKmonitor® Infliximab Total ADA ELISA (Health Canada)
Sample Type (Matrix): Serum, EDTA Plasma
Sample Volume: 25 µl
Incubation time: 3h
Size: 96 wells
Regulatory Status: Health Canada Licensed. Not for sale in U.S.
Kit Manual: Download
The IDKmonitor® Infliximab Total ADA ELISA is intended for the determination of human antibodies against TNFα blocker infliximab (e.g. REMICADE®) in the presence of infliximab in EDTA plasma and serum.
Health Canada Licensed. For Laboratory Professional Use Only.
Not for sale in the U.S. Please contact us to order or get a quote.
If you are in the U.S., you can purchase the RUO version of the Infliximab Total ADA ELISA.
Browse our other IDKmonitor® Infliximab ELISAs.
Test Principle of the IDKmonitor® Infliximab Total ADA ELISA
The IDKmonitor® Infliximab Total ADA ELISA is used for the determination of antibodies against TNFα-Blocker infliximab (e. g. REMICADE®).
During sample preparation, the anti-drug antibodies (ADA) are separated from the therapeutic antibody in order to acquire free ADA. By adding the conjugate (peroxidase-labeled therapeutic antibody) and the tracer (biotinylated therapeutic antibody), the unmarked therapeutic antibodies are replaced, and the marked antibodies can form a complex with the ADA. This complex binds via biotin to the streptavidin-coated microtiter plate. It is detected via the peroxidase conjugate with the peroxidase converting the substrate TMB to a blue product.
The enzymatic reaction is stopped by adding an acidic solution. The samples convert from blue to yellow. The color change should be measured in a photometer at 450 nm. The interpretation is made using the cut-off control.
|6.5 × 10 × 4.5 in